Timing of TAVR After Coronary Stent Placement
For bare-metal stents, wait at least 4-6 weeks before performing TAVR; for drug-eluting stents, wait at least 6 months (ideally up to 12 months) before TAVR to minimize the risk of stent thrombosis. 1, 2
Algorithmic Approach Based on Stent Type
Bare-Metal Stents (BMS)
- Minimum waiting period: 4-6 weeks 1, 2
- This timeframe allows for endothelialization of the stent, after which stent thrombosis becomes exceedingly rare (less than 0.1%) 2
- Dual antiplatelet therapy (aspirin + clopidogrel) should be maintained for at least 4-6 weeks after BMS placement 3
- Do not delay beyond 12 weeks, as restenosis may begin to occur 2
Drug-Eluting Stents (DES)
- Minimum waiting period: 6 months 1
- Optimal waiting period: 12 months 2, 4
- DES require prolonged dual antiplatelet therapy (6-12 months minimum) due to delayed endothelialization 3
- Late stent thrombosis remains a significant risk with premature discontinuation of antiplatelet therapy 1
Critical Decision Points
If TAVR Cannot Be Delayed
When surgery must proceed within the recommended timeframes:
- Continue dual antiplatelet therapy perioperatively rather than stopping both agents 1
- Alternative approach: Maintain aspirin and stop clopidogrel 5-7 days before TAVR 3, 2
- Resume clopidogrel as soon as possible post-TAVR, potentially with a 300 mg loading dose 3
High-Risk Stent Thrombosis Features
Patients requiring extra caution include those with 3:
- Multiple stents or long stents
- Stents at bifurcations
- Left main stenting
- History of prior stent thrombosis
- Diabetes mellitus
- Low ejection fraction
- Incomplete revascularization
Antiplatelet Management Around TAVR
Post-TAVR antiplatelet therapy: The 2014 AHA/ACC guidelines suggest dual antiplatelet therapy (aspirin 75-100 mg daily plus clopidogrel 75 mg daily) for the first 6 months after TAVR 5. This creates a favorable overlap with the required antiplatelet therapy for recent coronary stents.
Common Pitfalls to Avoid
- Do not place DES if TAVR is planned within 12 months - use BMS instead 3
- Never abruptly stop both antiplatelet agents in patients with recent stents - this is the strongest predictor of stent thrombosis 1
- Avoid bridging therapy with glycoprotein IIb/IIIa inhibitors, cangrelor, or LMWH - evidence does not support routine use 1, 6
- Do not assume all patients need pre-TAVR PCI - the benefit of revascularization in TAVR candidates remains controversial, particularly for non-proximal lesions 7, 8, 9
Multidisciplinary Team Discussion Required
Before proceeding with TAVR in patients with recent stents, convene a team meeting including 3:
- Interventional cardiologist
- Structural heart specialist
- Cardiac surgeon
- Anesthesiologist
- Hematologist (if complex bleeding risk)
Document the risk-benefit analysis of bleeding versus thrombosis and the agreed-upon antiplatelet management strategy.
Practical Considerations
The 2022 CHEST guidelines acknowledge substantial uncertainty about optimal management, noting that premature discontinuation of dual antiplatelet therapy within 6 weeks of BMS or 3-6 months of DES placement increases stent thrombosis risk and is the strongest predictor of this catastrophic complication 1, 6. Given that stent thrombosis results in Q-wave MI or death in the majority of cases 2, erring on the side of longer waiting periods is prudent when TAVR is not urgent.